16 September 2026 editorial review · Item
Autologous polyclonal Treg therapy (T-Rex program): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: T-Rex missed its randomized C-peptide endpoint (P=.94/.21). Phase 1 persistence does not overturn that result. July pooled immune-subtyping research is exploratory and did not test rescue of the Treg intervention.
- Registry NCT02691247: COMPLETED; updated 2021-01-08; enrollment 113 (ACTUAL); primary completion 2019-03 (ACTUAL); results posted.
- Primary publication/regulatory sources checked or consulted: scitranslmed.adn2404; scitranslmed.aad4134; s00125-026-06794-3.